# Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function

> **NCT00972374** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 44 (actual)

## Conditions studied

- Rhegmatogenous Macula-off Retinal Detachment

## Interventions

- **DRUG:** 400 ug Brimonidine Implant
- **DRUG:** 200 ug Brimonidine Implant
- **OTHER:** Sham (no implant)

## Key facts

- **NCT ID:** NCT00972374
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-10
- **Final completion:** 2011-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2013-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00972374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00972374, "Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00972374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*